<div id="readability-page-1">Pharmaceutical company Viatris (NASDAQ:VTRS) is set to announce its second quarter earnings result on Thursday, before the opening bell. Wall Street expects the Pennsylvania-based drugmaker to post EPS of $0.56, implying a fall of nearly 19% while revenue is expected to decline about 9% to $3.46 billion during the quarter. Over the last one year, V...</div>

晖致

<p>制药公司晖致（NASDAQ:VTRS）将在周四公布其第二季度财报，华尔街预计每股收益（EPS）为 0.56 美元，下降 19%，收入为 34.6 亿美元，下降 9%。晖致在过去一年中 75% 的时间里超出了每股收益和收入的预期。该股今年已下跌近 29%，主要归因于产品线的挫折和研发失败，导致分析师将其评级为持有。最近的修订显示每股收益和收入预期的变化喜忧参半</p>

晖致第二季度财报即将发布：有哪些值得期待的内容